Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia

References

• Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third national health and nutrition examination survey. Am J Kidney Dis. 2003;41:1–12. doi:10.1053/ajkd.2003.50007
   PubMed Web of Science ®Google Scholar
• Fishbane S, Spinowitz B. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018. Am J Kidney Dis. 2018;71:423–435. doi:10.1053/j.ajkd.2017.09.026
   PubMed Web of Science ®Google Scholar
• Silverberg DS, Wexler D, Blum M, et al. The cardio renal anemia syndrome: correcting anemia in patients with resistant congestive heart failure can improve both cardiac and renal function and reduce hospitalizations. Clin Nephrol. 2003;60(1):S93–102.
   PubMed Web of Science ®Google Scholar
• Mehdi U, Toto RD. Anemia, diabetes, and chronic kidney disease. Diabetes Care. 2009;32:1320–1326. doi:10.2337/dc08-0779
   PubMed Web of Science ®Google Scholar
• Swedberg K, Young JB, Anand IS, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368:1210–1219. doi:10.1056/NEJMoa1214865
   PubMed Web of Science ®Google Scholar
• Wanner C, Lachin JM, Inzucchi SE, et al. EMPA-REG OUTCOME Investigators. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation. 2018;137:119–129. doi:10.1161/CIRCULATIONAHA.117.028268
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295–2306. doi:10.1056/NEJMoa1811744
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. EMPEROR-reduced trial investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. DAPA-CKD trial committees and investigators. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446. doi:10.1056/NEJMoa2024816
   PubMed Web of Science ®Google Scholar
• Oshima M, Neuen BL, Jardine MJ, et al. Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial. Lancet Diabetes Endocrinol. 2020;8:903–914. doi:10.1016/S2213-8587(20)30300-4
   PubMed Web of Science ®Google Scholar
• Docherty KF, Curtain JP, Anand IS, et al. DAPA-HF investigators and committees. Effect of dapagliflozin on anaemia in DAPA-HF. Eur J Heart Fail. 2021;23:617–628. doi:10.1002/ejhf.2132
   PubMedGoogle Scholar
• Ferreira JP, Anker SD, Butler J, et al. Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-Reduced. Eur J Heart Fail. 2022;24:708–715. doi:10.1002/ejhf.2409
   PubMedGoogle Scholar
• Lambers Heerspink HJ, de Zeeuw D, Wie L, et al. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013;15:853–862. doi:10.1111/dom.12127
   PubMed Web of Science ®Google Scholar
• Maruyama T, Takashima H, Oguma H, et al. Canagliflozin improves erythropoiesis in diabetes patients with Anemia of chronic kidney disease. Diabetes Technol Ther. 2019;21:713–720. doi:10.1089/dia.2019.0212
   PubMed Web of Science ®Google Scholar
• Ghanim H, Abuaysheh S, Hejna J, et al. Dapagliflozin suppresses hepcidin and increases erythropoiesis. J Clin Endocrinol Metab. 2020;105(4):ii:dgaa057. doi:10.1210/clinem/dgaa057
   Web of Science ®Google Scholar
• KDOQI; National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11–145. doi:10.1053/j.ajkd.2006.03.010
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Miyajima H, Piperno A, et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol. 2010;45:1163–1171. doi:10.1007/s00535-010-0259-8
   PubMed Web of Science ®Google Scholar
• Docherty KF, Welsh P, Verma S, et al. Iron deficiency in heart failure and effect of dapagliflozin: findings from DAPA-HF. Circulation. 2022;146:980–994. doi:10.1161/CIRCULATIONAHA.122.060511
   PubMed Web of Science ®Google Scholar
• Pagani A, Nai A, Silvestri L, Camaschella C. Hepcidin and Anemia: a tight relationship. Front Physiol. 2019;10:1294. doi:10.3389/fphys.2019.01294
   PubMed Web of Science ®Google Scholar
• Stefánsson BV, Heerspink HJL, Wheeler DC, et al. Correction of anemia by dapagliflozin in patients with type 2 diabetes. J Diabetes Complications. 2020;34(12):107729. doi:10.1016/j.jdiacomp.2020.107729
   PubMed Web of Science ®Google Scholar
• Aberle J, Menzen M, Schmid SM, et al. Dapagliflozin effects on haematocrit, red blood cell count and reticulocytes in insulin-treated patients with type 2 diabetes. Sci Rep. 2020;10(1):22396. doi:10.1038/s41598-020-78734-z
   PubMed Web of Science ®Google Scholar
• Brands MW. Role of insulin-mediated antinatriuresis in sodium homeostasis and hypertension. Hypertension. 2018;72:1255–1262. doi:10.1161/HYPERTENSIONAHA.118.11728
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. The effect of insulin on renal sodium metabolism. A review with clinical implications. Diabetologia. 1981;21:165–171. doi:10.1007/BF00252649
   PubMed Web of Science ®Google Scholar
• Ferrannini E, Baldi S, Frascerra S, et al. Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes. Diabetes Care. 2017;40:771–776. doi:10.2337/dc16-2724
   PubMed Web of Science ®Google Scholar
• Besarab A, Provenzano R, Hertel J, et al. Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients. Nephrol Dial Transplant. 2015;30:1665–1673. doi:10.1093/ndt/gfv302
   PubMed Web of Science ®Google Scholar
• Bailey CJ, Day C, Bellary S. Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep. 2022;22:39–52. doi:10.1007/s11892-021-01442-z
   PubMed Web of Science ®Google Scholar